TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05910619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurolith Transcranial Pulse Stimulation Active
Description: 5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume \~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurolith Transcranial Pulse Stimulation Sham
Description: The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
Study: NCT04973007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadoxetate disodium
Description: Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadoxetate disodium
Description: Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobenate dimeglumine
Description: The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobenate dimeglumine
Description: The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
Study: NCT06165328

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and colonoscopy
Description: All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
Study: NCT05440734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2 Mg Oral Tablet, slow release
Study: NCT04754594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study: NCT05440734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill identical to the treatment pill
Study: NCT06106802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib 500mg/day
Study: NCT05697562

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rubber band ligatures (RBL)
Description: This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Rectal Artery Embolization (SRAE)
Description: This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Rectal Artery Embolization (SRAE)
Description: This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)
Description: The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
Study: NCT06461338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with sham electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
Study: NCT05859529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: The drug was administered by a single subcutaneous injection
Study: NCT04772534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study: NCT06615245

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No VR vs. immersive high tech VR
Description: No VR vs. immersive High Tech VR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plausible control vs immersive High Tech VR
Description: plausible control condition vs. immersive high tech VR
Study: NCT05289596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUT-i)
Description: SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
Study: NCT06404203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day
Description: Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day
Description: Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day
Description: Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo
Description: Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
Study: NCT05358275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical cutting guide with piezo
Description: 3D planned lid surgery
Study: NCT04572737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity plan to break up sitting time
Description: This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
Study: NCT05031975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 100 mg/smq intravenous infusion every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
Study: NCT05450900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriogonadotropin Alpha
Description: drug, active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Choriogonadotropin Alpha
Description: drug, active

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: biotin
Description: supplement, oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcellulose filler
Description: supplement, oral
Study: NCT04480554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-Naltrexone
Description: Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
Study: NCT04973670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: Sivelestat sodium 0.2mg/kg.h for 1-7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The same amount of NS containing only sivelestat sodium excipients
Study: NCT04893915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like NK cells
Description: Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like NK cells
Description: Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
Study: NCT05053633

Intervention type: PROCEDURE
Intervention: Combined spinal epidural anesthesia
Description: The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.
Study: NCT05081401

Intervention type: OTHER
Intervention: This is a non-intervention observational study.
Description: No applicable intervention. This is a secondary data analysis observational study.
Study: NCT04893915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: -Lymphodepleting regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: -Lymphodepleting regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Lymphodepleting regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Lymphodepleting regimen
Study: NCT04523857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study: NCT04893915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Leukapheresis
Description: -Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: -IL-2 will start approximately 2-4 hours after the NK cell infusions.
Study: NCT06495021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Pump Osteopathic Manipulative Therapy
Description: OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
Study: NCT06540963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: IV
Study: NCT06421584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical telementoring
Description: The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
Study: NCT05184582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
Study: NCT05974930

Intervention type: DEVICE
Intervention: IVUS imaging for primary PCI guidance
Description: Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
Study: NCT05188664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
Study: NCT05236608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered together with ADG106 via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: Administered as an intravenous infusion over 90 minutes.
Study: NCT05358275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: ordinary cyst enucleation
Study: NCT05859529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JS002
Description: The drug was administered by a single subcutaneous injection
Study: NCT06648707

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-task training
Description: Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-task training
Description: Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.
Study: NCT06190392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODS Modified simplified diagnostic strategy
Description: The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied.
Study: NCT05586555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pupillometry (Eve-tracking measurements)
Description: Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.

Intervention type: OTHER
Group type: OTHER
Intervention: Pupillometry (Eve-tracking measurements)
Description: Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
Study: NCT06467903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .
Description: second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
Study: NCT06091735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSS
Description: experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSS+Linzess
Description: experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG-Interferon Alfa
Description: Placebo Comparator
Study: NCT06178107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LP-LDL Probiotic
Description: LP-LDL a dietary food supplement probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo comparator Maltodextrin
Study: NCT05350163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Description: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
Study: NCT04893915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: -IL-2 will start approximately 2-4 hours after the NK cell infusions.